Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

References

• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity12(2), 121–127 (2000).
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre- B-cell growth-stimulating factor. Proc. Natl Acad. Sci. USA91(6), 2305–2309 (1994).
   PubMed Web of Science ®Google Scholar
• Bleul CC, Farzan M, Choe H et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature382(6594), 829–833 (1996).
   PubMed Web of Science ®Google Scholar
• Oberlin E, Amara A, Bachelerie F et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 [published erratum appears in Nature 1996 Nov 21;384(6606):288]. Nature382(6594), 833–835 (1996).
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature382(6592), 635–638 (1996).
   PubMed Web of Science ®Google Scholar
• Tachibana K, Hirota S, Iizasa H et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract [see comments]. Nature393(6685), 591–594 (1998).
   PubMed Web of Science ®Google Scholar
• Boldajipour B, Mahabaleshwar H, Kardash E et al. Control of chemokine-guided cell migration by ligand sequestration. Cell132(3), 463–473 (2008).
   PubMed Web of Science ®Google Scholar
• Sierro F, Biben C, Martinez-Munoz L et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl Acad. Sci. USA104(37), 14759–14764 (2007).
   PubMed Web of Science ®Google Scholar
• Hernandez PA, Gorlin RJ, Lukens JN et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet.34(1), 70–74 (2003).
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature410(6824), 50–56 (2001).
   PubMed Web of Science ®Google Scholar
• Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (New York, NY)283(5403), 845–848 (1999).
   Google Scholar
• Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity25(6), 977–988 (2006).
   PubMed Web of Science ®Google Scholar
• Sipkins DA, Wei X, Wu JW et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature435(7044), 969–973 (2005).
   PubMed Web of Science ®Google Scholar
• Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J. Exp. Med.195(9), 1145–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Cashen AF, Nervi B, Dipersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol.3(1), 19–27 (2007).
   PubMedGoogle Scholar
• Abraham M, Biyder K, Begin M et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells25(9), 2158–2166 (2007).
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell121(3), 335–348 (2005).
   PubMed Web of Science ®Google Scholar
• Moore KA, Lemischka IR. Stem cells and their niches. Science (New York, NY)311(5769), 1880–1885 (2006).
   Google Scholar
• Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell132(4), 598–611 (2008).
   PubMed Web of Science ®Google Scholar
• Laird DJ, Von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. Cell132(4), 612–630 (2008).
   PubMed Web of Science ®Google Scholar
• De Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol.13, 118–137 (2006).
   PubMedGoogle Scholar
• Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett.256(2), 137–165 (2007).
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metas. Rev.25(3), 357–371 (2006).
   PubMed Web of Science ®Google Scholar
• Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev.13(2), 143–154 (2002).
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat. Rev.4(7), 540–550 (2004).
   Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev.6(5), 392–401 (2006).
   Google Scholar
• Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle5(15), 1597–1601 (2006).
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol.169(5), 2756–2761 (2002).
   PubMed Web of Science ®Google Scholar
• Murphy PM. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med.345(11), 833–835 (2001).
   PubMed Web of Science ®Google Scholar
• Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell6(1), 17–32 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res.66(2), 605–612 (2006).
   PubMed Web of Science ®Google Scholar
• Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Investig.120(3), 694–705 (2010).
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood107(5), 1761–1767 (2006).
   PubMed Web of Science ®Google Scholar
• Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell124(1), 175–189 (2006).
   PubMed Web of Science ®Google Scholar
• Sandler A, Yi J, Dahlberg S et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J. Thorac. Oncol.5(9), 1416–1423 (2010).
   PubMed Web of Science ®Google Scholar
• Li YM, Pan Y, Wei Y et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell6(5), 459–469 (2004).
   PubMed Web of Science ®Google Scholar
• Su L, Zhang J, Xu H et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin. Cancer Res.11(23), 8273–8280 (2005).
   PubMed Web of Science ®Google Scholar
• Spano JP, Andre F, Morat L et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann. Oncol.15(4), 613–617 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner PL, Hyjek E, Vazquez MF et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J. Thorac. Cardiovasc. Surg.137(3), 615–621 (2009).
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12–CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med.167(12), 1676–1686 (2003).
   PubMed Web of Science ®Google Scholar
• Oonakahara K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M. Stromal-derived factor-1α/CXCL12–CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am. J. Respir. Cell. Mol. Biol.30(5), 671–677 (2004).
   PubMedGoogle Scholar
• Chen G, Wang Z, Liu XY, Liu FY. High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer. World J. Surg.35(1), 56–61 (2011).
   PubMedGoogle Scholar
• Wald O, Izhar U, Amir G et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J. Immunol.177(10), 6983–6990 (2006).
   PubMed Web of Science ®Google Scholar
• Simon Gr, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest132(3 Suppl.), 324S–339S (2007).
   PubMed Web of Science ®Google Scholar
• Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med.5(6), 662–668 (1999).
   PubMed Web of Science ®Google Scholar
• Burger M, Glodek A, Hartmann T et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene22(50), 8093–8101 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholson SA, Beasley MB, Brambilla E et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am. J. Surg. Pathol.26(9), 1184–1197 (2002).
   PubMed Web of Science ®Google Scholar
• Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int. J. Radiat. Biol.83(11–12), 733–741 (2007).
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood93(5), 1658–1667 (1999).
   PubMed Web of Science ®Google Scholar
• Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat. Rev. Immunol.6(2), 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Kijima T, Maulik G, Ma PC et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res.62(21), 6304–6311 (2002).
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene24(27), 4462–4471 (2005).
   PubMed Web of Science ®Google Scholar
• Tang CH, Tan TW, Fu WM, Yang RS. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis29(1), 35–43 (2008).
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med.3(7), 730–737 (1997).
   PubMed Web of Science ®Google Scholar
• Lessard J, Sauvageau G. BMI-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature423(6937), 255–260 (2003).
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature367(6464), 645–648 (1994).
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell11(1), 69–82 (2007).
   PubMed Web of Science ®Google Scholar
• Yang Zj, Wechsler-Reya Rj. Hit ‘em where they live: targeting the cancer stem cell niche. Cancer Cell11(1), 3–5 (2007).
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ.15(3), 504–514 (2008).
   PubMed Web of Science ®Google Scholar
• Bertolini G, Roz L, Perego P et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA106(38), 16281–16286 (2009).
   PubMed Web of Science ®Google Scholar
• Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br. J. Cancer102(11), 1636–1644 (2010).
   PubMed Web of Science ®Google Scholar
• Ooi AT, Mah V, Nickerson DW et al. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res.70(16), 6639–6648 (2010).
   Google Scholar
• Donnenberg VS, Luketich JD, Landreneau RJ, Deloia JA, Basse P, Donnenberg AD. Tumorigenic epithelial stem cells and their normal counterparts. Ernst Schering Found. Symp. Proc.5, 245–263 (2006).
   Google Scholar
• Levina V, Marrangoni AM, Demarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE3(8), e3077 (2008).
   PubMed Web of Science ®Google Scholar
• Liotta LA. An attractive force in metastasis. Nature410(6824), 24–25 (2001).
   PubMed Web of Science ®Google Scholar
• Nakashima H, Masuda M, Murakami T et al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother.36(6), 1249–1255 (1992).
   PubMed Web of Science ®Google Scholar
• Masuda M, Nakashima H, Ueda T et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem. Biophys. Res. Commun.189(2), 845–850 (1992).
   PubMed Web of Science ®Google Scholar
• De Clercq E, Yamamoto N, Pauwels R et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl Acad. Sci. USA89(12), 5286–5290 (1992).
   PubMed Web of Science ®Google Scholar
• De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol.77(11), 1655–1664 (2009).
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Grovit-Ferbas K, Sharron MP et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med.186(8), 1395–1400 (1997).
   PubMed Web of Science ®Google Scholar
• Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med.186(8), 1383–1388 (1997).
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakajima T, Koyanagi Y et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med.186(8), 1389–1393 (1997).
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov.2(7), 581–587 (2003).
   PubMed Web of Science ®Google Scholar
• Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett.527(1–3), 255–262 (2002).
   PubMed Web of Science ®Google Scholar
• Fricker SP, Anastassov V, Cox J et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol.72(5), 588–596 (2006).
   PubMed Web of Science ®Google Scholar
• Donzella GA, Schols D, Lin SW et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med.4(1), 72–77 (1998).
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Flexner C, Macfarland RT et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother.44(6), 1667–1673 (2000).
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier AC, Lederman MM et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr.37(2), 1253–1262 (2004).
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood102(8), 2728–2730 (2003).
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J. Clin. Oncol.22(6), 1095–1102 (2004).
   PubMed Web of Science ®Google Scholar
• Devine SM, Vij R, Rettig M et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood112(4), 990–998 (2008).
   PubMed Web of Science ®Google Scholar
• De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol. Therap.128(3), 509–518 (2010).
   PubMed Web of Science ®Google Scholar
• Dipersio JF, Stadtmauer EA, Nademanee A et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood113(23), 5720–5726 (2009).
   PubMed Web of Science ®Google Scholar
• Dipersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat. Rev. Drug Discov.8(2), 105–106 (2009).
   PubMedGoogle Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia23(1), 43–52 (2009).
   PubMed Web of Science ®Google Scholar
• Stone ND, Dunaway SB, Flexner C et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob. Agents Chemother.51(7), 2351–2358 (2007).
   PubMed Web of Science ®Google Scholar
• Tamamura H, Xu Y, Hattori T et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun.253(3), 877–882 (1998).
   PubMed Web of Science ®Google Scholar
• Tamamura H, Omagari A, Hiramatsu K et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett.11(14), 1897–1902 (2001).
   PubMed Web of Science ®Google Scholar
• Trent JO, Wang ZX, Murray JL et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem.278(47), 47136–47144 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang WB, Navenot JM, Haribabu B et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem.277(27), 24515–24521 (2002).
   PubMed Web of Science ®Google Scholar
• Kohara H, Omatsu Y, Sugiyama T, Noda M, Fujii N, Nagasawa T. Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12–CXCR4 chemokine signaling. Blood110(13), 4153–4160 (2007).
   PubMed Web of Science ®Google Scholar
• Kabashima K, Shiraishi N, Sugita K et al. CXCL12–CXCR4 engagement is required for migration of cutaneous dendritic cells. Am. J. Pathol.171(4), 1249–1257 (2007).
   PubMed Web of Science ®Google Scholar
• Allen CD, Ansel KM, Low C et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol.5(9), 943–952 (2004).
   PubMed Web of Science ®Google Scholar
• Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol.3(7), 687–694 (2002).
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Filion LG, Diaz-Mitoma F et al. Safe use of the CXCR4 inhibitor ALX40–4C in humans. AIDS Res. Hum. Retroviruses17(6), 475–486 (2001).
   PubMed Web of Science ®Google Scholar
• Endres MJ, Clapham PR, Marsh M et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell87(4), 745–756 (1996).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Dell’agnola C, Mancuso P et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res.62(11), 3106–3112 (2002).
   PubMed Web of Science ®Google Scholar
• Engl T, Relja B, Marian D et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins. Neoplasia8(4), 290–301 (2006).
   PubMed Web of Science ®Google Scholar
• Baribaud F, Edwards TG, Sharron M et al. Antigenically distinct conformations of CXCR4. J. Virol.75(19), 8957–8967 (2001).
   PubMed Web of Science ®Google Scholar
• Farzan M, Babcock GJ, Vasilieva N et al. The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 α association and HIV-1 entry. J. Biol. Chem.277(33), 29484–29489 (2002).
   PubMed Web of Science ®Google Scholar
• Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin. Cancer Res.14(24), 7975–7980 (2008).
   PubMed Web of Science ®Google Scholar
• Perez LE, Alpdogan O, Shieh JH et al. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp. Hematol.32(3), 300–307 (2004).
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee CH, Midura BV et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis25(3), 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Hachet-Haas M, Balabanian K, Rohmer F et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J. Biol. Chem.283(34), 23189–23199 (2008).
   PubMed Web of Science ®Google Scholar
• Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet.8(3), 173–184 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res.63(16), 4801–4804 (2003).
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Blanchetot C, Maussang D et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl Acad. Sci. USA107(47), 20565–20570 (2010).
   PubMed Web of Science ®Google Scholar